X0206 3 2018-06-19 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001743881 BridgeBio Pharma LLC 421 KIPLING ST PALO ALTO CA 94301 0 0 1 0 Series Seed Preferred Stock Common Stock 15347219 D Series B Preferred Stock Common Stock 3081813 D Warrants 10.8348 Series B Preferred Stock 332262 D The preferred stock will automatically convert into the Issuer's Common Stock on a 1-to-1.196 basis upon the closing of the Issuer's initial public offering and has no expiration date. Immediately prior to completion of the Issuer's initial public offering, the warrants will automatically be exercised for shares of Series B Preferred Stock and such shares acquired will automatically be converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock. BridgeBio Pharma LLC By: /s/ Neil Kumar, Chief Executive Officer 2018-06-19